Edwards Lifesciences (NYSE: EW) awards RSUs and options to CVP Daveen Chopra

Rhea-AI Filing Summary

Edwards Lifesciences executive Daveen Chopra, CVP TMTT & Surgical, reported routine equity compensation and related tax withholding transactions in company stock. On May 7, 2026, he received 9,675 restricted stock units and 9,675 performance-based rights, plus 49,100 stock options with an $82.76 exercise price, all granted under the Long-Term Stock Incentive Compensation Program.

The restricted stock units and options are scheduled to vest in four equal annual installments starting one year after the grant date, while the performance rights are scheduled to vest on May 7, 2029 based on three-year performance goals, with 0%–200% of the target potentially vesting. On May 7–8, 2026, a total of 1,815 shares of common stock were disposed of solely to cover tax obligations, not as open-market sales. After these transactions, Chopra directly holds 39,779 shares of common stock.

Insights

Equity compensation and governance analyst

Routine equity grants and tax withholding with no open-market insider buying or selling.

Daveen Chopra received time-based restricted stock units, performance-based stock units, and stock options under the Edwards Lifesciences Long-Term Stock Incentive Compensation Program. The options have an $82.76 exercise price and the awards vest over several years, aligning compensation with long-term performance.

Two transactions on May 7–8, 2026 involved a combined 1,815 shares withheld at prices around $83 per share to satisfy tax liabilities. These are coded as tax-withholding dispositions rather than discretionary sales, so they do not represent open-market trading decisions.

Following the reported activity, Chopra directly holds 39,779 common shares, plus unvested awards including performance rights that can vest from 0% to 200% of target by May 7, 2029, depending on achievement of specified performance goals. The events appear consistent with standard executive compensation practices.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Chopra Daveen

Role CVP, TMTT & Surgical

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,141	$82.76	$94K
Grant/Award	Employee Stock Option (Right to Acquire)	49,100	$0.00	--
Grant/Award	Performance Rights	9,675	$0.00	--
Grant/Award	Common Stock	9,675	$0.00	--
Tax Withholding	Common Stock	674	$83.20	$56K

Holdings After Transaction: Common Stock — 39,779 shares (Direct, null); Employee Stock Option (Right to Acquire) — 49,100 shares (Direct, null); Performance Rights — 9,675 shares (Direct, null)

Footnotes (1)

1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Key Figures

Tax-withheld shares: 1,815 shares RSU grant: 9,675 shares Performance rights target: 9,675 shares +4 more

7 metrics

Tax-withheld shares 1,815 shares Shares disposed May 7–8, 2026 for tax withholding

RSU grant 9,675 shares Restricted stock units granted May 7, 2026

Performance rights target 9,675 shares Performance-based units granted May 7, 2026, vesting May 7, 2029

Option grant size 49,100 options Employee stock options granted May 7, 2026

Option exercise price $82.76 per share Exercise price for employee stock options

Common shares held 39,779 shares Direct ownership after transactions

Tax-withholding prices $82.76 and $83.20 Per-share values used for tax-withholding dispositions

Key Terms

restricted stock units, Performance Rights, Employee Stock Option (Right to Acquire), tax-withholding disposition, +2 more

6 terms

restricted stock units financial

"These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance Rights financial

"Security title: Performance Rights with underlying common stock and performance-based vesting"

Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.

Employee Stock Option (Right to Acquire) financial

"Security title: Employee Stock Option (Right to Acquire) with an $82.7600 conversion or exercise price"

tax-withholding disposition financial

"transaction_action: tax-withholding disposition for payment of exercise price or tax liability"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Long-Term Stock Incentive Compensation Program financial

"granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program"

performance goals over a three-year performance period financial

"The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chopra Daveen

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TMTT & Surgical

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A		9,675(1)	A	$0.0000	41,594	D
Common Stock	05/07/2026		F		674	D	$83.2	40,920	D
Common Stock	05/08/2026		F		1,141	D	$82.76	39,779	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$82.76	05/07/2026		A		49,100		05/07/2027(2)	05/06/2033	Common Stock	49,100	$0.0000	49,100	D
Performance Rights	(3)	05/07/2026		A		9,675		05/07/2029	(3)	Common Stock	9,675	$0.0000	9,675	D

Explanation of Responses:

1. These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

2. These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

3. Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did EW executive Daveen Chopra receive in this Form 4?

Daveen Chopra received 9,675 restricted stock units, 9,675 performance-based rights, and 49,100 employee stock options with an $82.76 exercise price. All awards were granted on May 7, 2026 under Edwards Lifesciences’ Long-Term Stock Incentive Compensation Program.

How and when will Daveen Chopra’s new Edwards Lifesciences equity awards vest?

The restricted stock units and options vest in four equal annual installments starting one year after the May 7, 2026 grant date. The performance rights are scheduled to vest on May 7, 2029, based on three-year performance goals, with 0%–200% of target potentially vesting.

Were there any open-market stock sales by Daveen Chopra in this EW Form 4?

No open-market sales are reported. The Form 4 shows two F-code transactions totaling 1,815 shares, both described as tax-withholding dispositions to cover exercise price or tax liabilities, not discretionary market sales or purchases of Edwards Lifesciences common stock.

How many Edwards Lifesciences shares does Daveen Chopra hold after these transactions?

After the reported transactions, Daveen Chopra directly holds 39,779 shares of Edwards Lifesciences common stock. This figure reflects his direct ownership following the equity grants and the share dispositions used to satisfy related tax obligations reported in the Form 4.

What performance conditions apply to Daveen Chopra’s Edwards Lifesciences performance rights?

The performance rights reflect a target 9,675 shares and are scheduled to vest on May 7, 2029. Actual vesting depends on achieving specified performance goals over a three-year period, with the payout ranging from 0% to 200% of the target award.

What is the significance of the $82.76 exercise price on Chopra’s EW stock options?

The $82.76 exercise price is the cost per share for Daveen Chopra to purchase Edwards Lifesciences stock under his 49,100 stock options. These options vest in four annual installments beginning one year after the May 7, 2026 grant date.